Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 27-07-2015 | Practice Area: | Corporate and M&A |
| Deal Title: | AstraZeneca Divestment of Caprelsa to Genzyme | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
AstraZeneca announced that it had entered into a definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine. Under the terms of the agreement, Genzyme would pay AstraZeneca up to USD300 million, including an upfront payment of USD165 million to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to USD135 million.
|
||
| Financial Center: | Birmingham | Value: | 100.01-500.00 |
| Advised Party: | Vendor | Law Firm | Gowling WLG |
| Target Company Jurisdiction: | United Kingdom | Acquiror Jurisdiction: | United Kingdom |
| Classification: |
Strategic Buyer Acquisitions Asset Sales |
Lawyer | Patrick Duxbury |
